Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Age Range:Any - 18
Start Date:May 2014
End Date:March 2020
Contact:Karen Fusaro

Use our guide to learn which trials are right for you!

An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)

The purpose of this Phase 1 trial is to evaluate the pharmacokinetics, safety and
tolerability of oritavancin in patients <18 years old with a confirmed or suspected bacterial

This is a Phase 1, multicenter, open-label, PK, safety and tolerability study of oritavancin
in pediatric patients (<18 years of age) with suspected or diagnosed Gram-positive bacterial
infections or pediatric patients requiring peri-operative prophylactic antibiotics.
Approximately 52 patients will be enrolled at 5-10 US centers. This study will include 5 age
cohorts and patients will be entered in a stepwise approach starting with the older age
cohort (12-<18 years). The starting dose will be IV oritavancin 15 mg/kg. The safety,
tolerability and PK data will be reviewed at the completion of each cohort to ensure safety
and determine the appropriate dose for the next age cohort. At least 8 patients will be
enrolled in each cohort except for the birth to <3 month age cohort which will have at least
16 patients enrolled. Three PK samples will be collected over 14 days. The safety follow-up
will complete with a 60-day phone call to the caregiver.

Inclusion Criteria:

- Males and females <18 years of age

- Neonates must be at least 34 weeks post-conception age

- Parent or legal guardian has given informed consent, as appropriate; and pediatric
patient has given verbal assent where appropriate.

- Suspected or diagnosed Gram positive bacterial infection for which the subject is
receiving standard antibiotic therapy; or peri-operative prophylactic use of

- Intravenous access to administer study drug

- The subject will be observed in the emergency room or hospital for at least 1 hour
after the study drug infusion is completed.

Exclusion Criteria:

- Septic shock or acute haemodynamic instability.

- History of immune-related hypersensitivity reaction to glycopeptides (such as
vancomycin, dalbavancin, televancin, or teicoplanin) or any of their excipients.

- Subjects who have taken vancomycin, telavancin, teicoplanin or other glycopeptide
within 24 hours of screening or who are anticipated to need these drugs within 48
hours after administration of study drug. Subjects who have taken dalbavancin are
excluded if taken within the previous 2 weeks or who are anticipated to need
dalbavancin within 48 hours after administration of study drug.

- Females who are of childbearing potential and unwilling to practice abstinence or use
at least two methods of contraception or female patients of childbearing who are
lactating or have a positive pregnancy test result at screening

- Males who are unwilling to practice abstinence or use an acceptable method of birth
control during the entire study period

- Any surgical or medical condition which, in the opinion of the investigator, would put
the patient at increased risk or is likely to interfere with study procedures or PK of
the study drug.

- Patients whom the investigator considers unlikely to adhere to the protocol, comply
with study drug administration, or complete the clinical study

- Treatment with investigational medicinal product or investigational device within 30
days (or 5 times the half-life of the investigational medicine, whichever is longer)
before enrollment and for the duration of the study.

- Any clinically significant disease or condition affecting a major organ system,
including but not limited to gastrointestinal, renal, hepatic, endocrinologic,
broncho-pulmonary, neurological, metabolic or cardiovascular disease.
We found this trial at
Orange, California 92868
Principal Investigator: Antonio Arrieta, MD
Phone: 714-509-4791
Orange, CA
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
(216) 844-1000
Principal Investigator: David Speicher, MD
Phone: 216-844-5112
Rainbow Babies and Children's Hospital UH Rainbow Babies & Children’s Hospital is a 244-bed, full-service...
Cleveland, OH
Click here to add this to my saved trials
3020 Childrens way
San Diego, California 92123
(858) 576-1700
Principal Investigator: John Bradley, MD
Phone: 858-966-8450
Rady Children's Hospital - San Diego Rady Children's Hospital-San Diego is the region’s pediatric medical...
San Diego, CA
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: Jose R Romero, MD
Phone: 501-364-1542
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
Little Rock, AR
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Claudia Espinosa, MD
Louisville, KY
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Principal Investigator: Kari A Simonsen, MD
Phone: 402-559-0681
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
Omaha, NE
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Principal Investigator: Sharon Nachman, MD
Phone: 631-444-8225
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
Stony Brook, NY
Click here to add this to my saved trials
Toledo, Ohio 43606
Principal Investigator: Jeffrey Blumer, PhD, MD
Phone: 419-291-2191
Toledo, OH
Click here to add this to my saved trials
Torrance, California 90509
Principal Investigator: James A McKinnell, MD
Phone: 310-222-5693
Torrance, CA
Click here to add this to my saved trials